Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence
Authors:
- Gbolahan OlatunjiGOGbolahan Olatunji
- Nicholas AderintoNANicholas Aderinto
- Emmanuel KokoriEKEmmanuel Kokori
- Michael AwoyinfaMAMichael Awoyinfa
- Oluwafemi AjimotokanOAOluwafemi Ajimotokan
- Joan Oluwadamilola AjayiJAJoan Oluwadamilola Ajayi
- Nitin Narayan RaoNRNitin Narayan Rao
- Ajayi Oluwatomisin TemidayoATAjayi Oluwatomisin Temidayo
- Tejiri NapoleonTNTejiri Napoleon
- Chimezirim EzeanoCEChimezirim Ezeano
- Sulaimon Olaide BukkySBSulaimon Olaide Bukky
- Emmanuel Elorm Nortey-AdomENEmmanuel Elorm Nortey-Adom
Open Access
- 25 November 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 548-553
Abstract
Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.Keywords
This publication has 18 references indexed in Scilit:
- Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)European Journal of Cancer, 2024
- Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancerNature Communications, 2023
- Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyThe Lancet Oncology, 2023
- Dual targeted therapy with pyrotinib and trastuzumab forHER2‐positive advanced colorectal cancer: A phase 2 trialCancer Science, 2022
- Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatmentBMC Cancer, 2022
- Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trialNature Medicine, 2021
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyThe Lancet Oncology, 2019
- Final Results of the HERACLES trial in HER2 amplified colorectal cancerAnnals of Oncology, 2016
- Pathophysiology, Clinical Presentation, and Management of Colon CancerGastroenterology Clinics of North America, 2008
- Spiral CT of Colon Cancer: Imaging Features and Role in ManagementRadioGraphics, 2000